IMV Inc IMVIF

RE:Fred Ors answer to D. Novak

[qwerty22]

That's super helpful.

The suggestion here is that the data they presented yesterday PLUS data Merck holds privately is what supports the path forward. The point being the data presented yesterday is not enough on it's own. We have to trust in Fred he has this right. He went on to say something about already being in advanced conversations with Merck, I don't suppose you could copy that part here? I'm struggling to re-activate my SA login. I wonder if Merck hold important data to more clearly answer some of these questions how they will be able to communicate that to us. From Fred's follow on statement I thought there was a suggestion he would.


It all boils down to whether dpx+pembro is SUPERIOR to pembro-alone. It MUST BE superior in order to justify dpx's inclusion in the combo. The present trial was not designed to answer that question so people try to answer it by comparing to other studies head-to-head. This is a very imperfect way to do things, there are many issues with doing that but there is no other way to try to answer this question. IMV attempt it it on slide 15 with two studies that suggest pembro+dpx is superior, the analyst uncovered another study that suggests non-superiority.

With the 86% ORR it seems very likely that there will be a next trial. The obvious thing to do next is a direct head-to-head comparison between dpx-pembro and pembro-alone (and throw in dpx-alone for good measure). People want to know that trial will be successful and unfortunately as it stands that's ambiguous.

My position is I'm neither buying or selling. There is more info (from Merck) that can clarify this, I'm waiting to see if we get it.

Any analyst notes yet?

 

Breakthorough wrote: "Frederic Ors Thanks, David. Just as a reminder, the studies is done in collaboration with Merck. So, we are not making decisions alone on the interpretation of the results. And, obviously, Merck has a lot more information than what is published and that we have access to in terms of PD-L1 correlation in DLBCL. And so, we are very confident that the highest level of responses that we have combined with the fact that there are no responses without PD-L1 is statistically significant and different from what they have seen and what their plans are currently." https://seekingalpha.com/article/4388574-imv-inc-imv-ceo-frederic-ors-on-q3-2020-results-earnings-call-transcript?mod=mw_quote_news